Prevention and treatment of traveler's diarrhea - Focus on antimicrobial agents

被引:15
作者
Castelli, F [1 ]
Saleri, N [1 ]
Tomasoni, LR [1 ]
Carosi, G [1 ]
机构
[1] Univ Brescia, Inst Infect & Trop Dis, Sch Med & Dent, IT-25123 Brescia, Italy
关键词
Traveler's diarrhea; treatment and prevention; diarrhea; antibiotic chemoprophylaxis; rifaximin;
D O I
10.1159/000089786
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Diarrhea, mostly due to bacterial infection of the gut, is the most frequent health complaint in the international traveler, affecting 20-70% of the traveling population depending on the destination and other factors. It is usually benign and self-limiting in nature, but symptoms may occasionally be distressing causing modifications of normal activities and sometimes confinement to bed or hospitalization. Prevention of traveler's diarrhea should ideally be based on dietary restrictions, but experience shows that this target is extremely difficult to achieve. Antibiotic chemoprophylaxis should be restricted to selected groups of travelers at risk of severe complications of diarrhea or when diarrhea-driven alterations of planned activities are highly undesirable (critical trips). The effectiveness of alternative prophylactic approaches, such as vaccination or the use of probiotics, still awaits confirmation. Treatment of mild diarrheal cases without intestinal symptoms may be limited to rehydration with or without antimotility agents. When antibiotic therapy is considered, non-absorbable antibiotics, such as rifaximin, may be considered a valid alternative to systemic antibiotics to treat uncomplicated cases, leaving fluoroquinolones and/or azithromycin for use in more severe cases or when invasive pathogens are suspected. Indeed, therapeutic use of doxycycline and trimethoprim-sulfamethoxazole (TMP-SMX) is limited by widespread resistance of many enteropathogens. The addition of loperamide or other antimotility agents usually provides symptom relief and further shortens the duration of illness and may be therefore safely adopted in the healthy adult unless dysentery is present.
引用
收藏
页码:109 / 118
页数:10
相关论文
共 65 条
  • [1] Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico
    Adachi, JA
    Ericsson, CD
    Jiang, ZD
    DuPont, MW
    Martinez-Sandoval, F
    Knirsch, C
    DuPont, HL
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) : 1165 - 1171
  • [2] Traveller's diarrhoea
    Al-Abri, SS
    Beeching, NJ
    Nye, FJ
    [J]. LANCET INFECTIOUS DISEASES, 2005, 5 (06) : 349 - 360
  • [3] TRIMETHOPRIM SULFAMETHOXAZOLE REMAINS ACTIVE AGAINST ENTEROTOXIGENIC ESCHERICHIA-COLI AND SHIGELLA SPECIES IN GUADALAJARA, MEXICO
    BANDRES, JC
    MATHEWSON, JJ
    ERICSSON, CD
    DUPONT, HL
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1992, 303 (05) : 289 - 291
  • [4] Castelli F, 2004, J TRAVEL MED, V11, P1
  • [5] Epidemiology of travelers' diarrhea
    Castelli, F
    Pezzoli, C
    Tomasoni, L
    [J]. JOURNAL OF TRAVEL MEDICINE, 2001, 8 : S26 - S30
  • [6] EPIDEMIOLOGY OF TRAVELERS DIARRHEA
    CASTELLI, F
    CAROSI, G
    [J]. CHEMOTHERAPY, 1995, 41 : 20 - 32
  • [7] Connor BA, 2004, INFECT MED, V21, P18
  • [8] Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis
    D'Souza, AL
    Rajkumar, C
    Cooke, J
    Bulpitt, CJ
    [J]. BRITISH MEDICAL JOURNAL, 2002, 324 (7350): : 1361 - 1364
  • [9] ORAL AZTREONAM, A POORLY ABSORBED YET EFFECTIVE THERAPY FOR BACTERIAL DIARRHEA IN UNITED-STATES TRAVELERS TO MEXICO
    DUPONT, HL
    ERICSSON, CD
    MATHEWSON, JJ
    DELACABADA, FJ
    CONRAD, DA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (14): : 1932 - 1935
  • [10] DUPONT HL, 1982, REV INFECT DIS, V4, P533